The Role of Liquid Biomarker for Early Detection of Prostate Cancer

Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.

Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.

Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.

Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.

David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

This article features insights from David Albala, MD, and Judd W. Moul, MD, on using liquid biomarker-based testing for the early detection of prostate cancer.